Mon, Dec 22, 2014, 12:16 AM EST - U.S. Markets open in 9 hrs 14 mins

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

  • duveldeuce duveldeuce Jan 19, 2010 10:26 PM Flag

    Cool New Article On Alnylam

    Phase Biotech, which provides clinical trial update information for doctors and not investors covered Alnylam. I think alot of those doctors will become investors though. But how long will it take for RNAi therapy to get approved?

    http://www.phasebiotech.com/

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Who is holding their dick now?

    • Ha Ha Ha.....

    • ISIS will be @$25 by Y/E alaylum $12....38 months of dead $$$$$$$$$$$ and JM will be still JM holding his dick in his hand.

    • Pothead, why don't you answer the points I raised about ISIS? You conveniently ignored them and bashed ALNY. POTHEAD, ANSWER my QUESTIONS about product and price appreciation!

    • So, you think that this technology is may years from being used? Ok, but how many? 3, 5, 10?

      Nice find on the article. GLTA

      • 1 Reply to zd_bar
      • zd . . . for Alnylam . . . AT LEAST ANOTHER DECADE!

        Look . . . it took ISIS more than 16 YEARS to figure out SAFE, EFFECTIVE drug DELIVERY for SINGLE-STRANDED RNA - - with 2nd & 3rd Generation Antisense Technology. . . and you may know one of Potted's most FAMOUS mantras . . . with RNAi . . . "Double-Stranded is DOUBLE TROUBLE!" . . . http://www1.investorvillage.com/smbd.asp?mb=569&mn=12354&pt=msg&mid=4436615

        Alnylam not only has to COPE with UNCONTROLLED and VARIABLE "TLR" effects with RNAi (Toll-like receptor effects . . . spoken by Dr. Ambati - - which now HAUNTS the Halls of Alnylam! . . . like a GHOST!) . . . since the human body views double-stranded RNAi as a VIRUS! . . . but the whole process of RNAi . . . it sometime makes INCOMPLETE COPIES ( like an over-worked Xerox machine! ) . . . and this leads to DOWNSTREAM OFF-TARGET GENE REGULATION! . . . ( a very BAD thing!!! ) . . . and a topic RARELY discusses by the Alnylam Dream Team! . . . and this is STILL a big, BIG problem YET to be RESOLVED . . . IF EVER!

        So Potted's BEST projection for SAFE and EFFECTIVE RNAi drug delivery . . . . is AT LEAST a decade from now . . . if it is ever accomplished. . . Let's face it . . . at the rate Alnylam is going now . . . and the PROBLEMS that keep RE-SURFACING! . . . with initial CLAIMS of SUCCESS! . . . and then the clinical trial TERMINATED! ( Shhh! . . . keep this quiet! . . that was Tekmira's latest SNALP trial FAILURE - - Alnylam's drug DELIVERY partner! ) . . It's like the "Dream Team" has their definitions of "SUCCESS" and "FAILURE" SWITCHED! . . . and then another Alnylam drug candidate "PARKED" . . . and another trial "Starting-Over" . . . just WHERE are the TANGIBLE SIGNS of PROGRESS? . . . Honestly . . . Just where are they???

        And zd . . . all we get from JM is more FALSE PROMISES! . . . ( e.g. two BIG partnership deals in 2009! ) . . . As you may know . . . Potted called for JM's dismissal many moons ago . . . he was RIGHT for Alnylam in the early developmental days . . . to generate early EXCITEMENT in the field with "dreamy promises" of the RNAi technology! . . . and NO ONE could do it better than JM! . . . but when it comes to hard, HARD therapeutic drug development . . . and the expected failures in human CLINICAL Trials . . . and developing a SUCCESSFUL STRATEGY for all of that . . . and a COMMUNICATION strategy for the shareholders . . . well . . . JM just comes up SHORT! . . . that's NOT his strong suit!

        So for Alnylam . . . Potted not ONLY questions the success prospects for RNAi . . . but Potted also QUESTIONS the top management now at Alnylam! . . . and that's why Potted thinks the ALNY stock price has FURTHER to DROP! . . . and that's why Potted says . . .

        Go to the Head-of-the-Class with ISIS!

    • << But how long will it take for RNAi therapy to get approved? >>

      In Potted's view . . . at LEAST a DECADE! . . . Just READ what Alan Sachs, Vice President, RNA Therapeutics, Merck Research Laboratories had to say about RNAi . . . "Merck’s Alan Sachs, on RNAi’s Big Challenge: Delivery, Delivery, Delivery" . . . http://www.xconomy.com/national/2010/01/21/mercks-alan-sachs-on-rnais-big-challenge-delivery-delivery-delivery/

      Here's the "take away" . . .

      1) According to Alan . . . Liposomal delivery for RNAi is very PROBLEMATIC! . . . SAFETY is the BIGGEST CONCERN! . . . and LOOK . . . . we just saw Tekmira's ApoB SNALPs FAIL! . . . and Alnylam is now SCRUBBING any PR documents for the words "Tekmira" . . . and "SNALPs!"

      2) Merck now sees the greatest potential for RNAi as a "lab technique" . . . for drug target VALIDATION! . . . to "de-risk" small-molecule drug development! . . . Actual "workable" RNAi drug therapeutics are many, MANY YEARS away!

      3) The REQUIRED IV drug administration for RNAi-based drugs LIMITS the overall market potential for RNAi! . . . RNAi for Cancer . . . Possibly yes! . . . but RNAi for chronic diseases . . . such as Cardiovascular diseases . . . Metabolic diseases ( Diabetes, etc. ) . . . and other chronic diseases . . . LIKELY NO! . . . the IV drug delivery is NOT APPROPRIATE!

      4) The "deflation" in the RNAi "gas-bag!" will continue over the next few years! . . . JM's proposed 2009 "deals" VAPORIZED because the bio-market NOW KNOWS that the "State of RNAi in 2010" is still VERY IMMATURE!

      Go to the Head-of-the-Class with ISIS!

    • many years

 
ALNY
100.73+1.320(+1.33%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.